NICE gives draft thumbs-up to Novartis inhaler; Mylan earnings leap 35%;

@FiercePharma: Novartis puts off restart at Lincoln, Neb., plant... again. Fed-up CEO says no more predictions--Bloomberg. News | Follow @FiercePharma

> The U.K.'s National Institute for Health and Clinical Excellence made a draft recommendation in favor of Novartis' ($NVS) lung treatment Tobi Podhaler. Report

> Generics maker Mylan ($MYL) posted a 35% increase in third-quarter earnings on a double-digit sales increase to $1.81 billion. Report

> Abbott Laboratories ($ABT) said its ALK genetic test is now available in Europe to identify patients suitable for Pfizer's ($PFE) targeted lung cancer drug Xalkori. Report

> Pharma manufacturers don't have a great reputation online, a new survey found, but social media may help change that. Report

> The U.K.'s cost-effectiveness watchdog says medicine prices in the country are under control, with costs falling by 0.4% over the past year. Report

Medical Device News

 @FierceMedDev: Alere warned by FDA for cardio Dx quality shortfalls. Item | Follow @FierceMedDev

 @MarkHFierce: A Senate report blasts Medtronic for improperly shaping data regarding its Infuse bone graft, all to boost sales. Story | Follow @MarkHFierce

 @DamianFierce: 2012 was less than a banner year for med device and diagnostic IPOs. We take a look at the numbers: Report | Follow @DamianFierce

> J&J's Ethicon hit with Class I over stapler recall. News

> FDA chides St. Jude over CRM plant. Story

Biotech News

 @FierceBiotech: From Swedish bioinformatics group grabs $840K to fuel growth, report says. More | Follow @FierceBiotech

 @JohnCFierce: Signs of life? Top 10 biotech IPOs. Special Report | Follow @JohnCFierce

 @RyanMFierce: GSK's SROne leads $35M round for Thrasos Therapeutics for PhII study of kidney injury treatment. Release | Follow @RyanMFierce

> Ex-Geron chief spearheads bid to revive mothballed stem cell studies. News

> Shire chief prepares to hand over reins to hand-picked successor. Story

> Profit plunge stokes M&A buzz as AstraZeneca chief vows to strike more deals. Report

@AlisonBFierce: U. of Texas at Austin researchers got $6.5M from Dept. of Defense to develop new vaccines for emerging health threats. More | Follow @AlisonBFierce

> Italy bans Novartis influenza vaccines. News

> CDC green-lights GSK's meningitis vaccine for at-risk infants. Item

> HIV antibody development discovery advances vaccine search. Story

> EMA: 'Insufficient' link between narcolepsy and GSK flu vaccine. Report

> Novavax reports positive avian flu vaccine results. Article

Pharma Manufacturing News

> DSM snags another project to feed Australian biologics plant. More

> Novartis CEO defends manufacturing lapses. Article

> FDA group argues for helping poor countries beef up oversight. Story

And Finally... Sun Pharma's Dilip Shanghvi jumped into the top 5 on Forbes' list of wealthiest Indians. Report

Suggested Articles

Late-stage ovarian cancer patients have few options, but now the FDA is reviewing GSK's Zejula for the patient group.

The FDA has raised questions about the manufacturing of Glenmark's new molecular entity Ryaltris, a nasal spray for seasonal allergic rhinitis.

Despite unconventional support from President Donald Trump, Johnson & Johnson’s Spravato didn’t win broad backing at the VA.